Hospital
Humc Opco LLC
Humc Opco LLC was paid $57.36M by Medicaid between Jan 2018 and Dec 2024, across 261 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoHUMC OPCO LLC
HOBOKEN, NJ 07030
HOBOKEN, NJ 07030
33aNPI1043475668assigned 07/23/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$57.36M
24GClaims970,850
24DCodes billed261
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#28 of 93
Median peer was paid$30.60M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 154,933 | $10.82M | |
| 2019 | 137,732 | $9.77M | |
| 2020 | 95,223 | $7.06M | |
| 2021 | 117,366 | $7.79M | |
| 2022 | 168,912 | $8.86M | |
| 2023 | 178,057 | $7.46M | |
| 2024incomplete | 118,627 | $5.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 43,107 | 37,101 | $13.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 22,076 | 19,754 | $7.53M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.9% | 12,975 | 11,608 | $5.11M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 8.5% | 44,258 | 19,468 | $4.85M |
| G0378 | Hospital observation service, per hour | 8.3% | 6,925 | 4,716 | $4.78M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.0% | 21,303 | 18,247 | $4.57M |
| OP250 | 3.5% | 64,515 | 46,968 | $2.02M | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.0% | 13,601 | 12,935 | $1.70M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 1.2% | 4,423 | 4,181 | $709K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 4,262 | 3,700 | $701K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 1.1% | 6,908 | 777 | $650K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 16,056 | 3,578 | $564K |
249 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 732 | $524K |
| 93017 | <1% | 882 | $495K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,192 | $403K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,176 | $400K |
| OP272 | <1% | 27,299 | $326K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,964 | $320K |
| 80053 | Comprehensive metabolic panel | <1% | 40,275 | $288K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 4,984 | $276K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,422 | $263K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,527 | $261K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,103 | $251K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 328 | $248K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,732 | $246K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,701 | $234K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,611 | $207K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,454 | $191K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 6,170 | $187K |
| 76830 | Ultrasound, transvaginal | <1% | 1,767 | $182K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 24,321 | $180K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,285 | $179K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 6,293 | $159K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,747 | $153K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,304 | $152K |
| 81025 | <1% | 17,017 | $146K | |
| 82948 | <1% | 19,857 | $136K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,924 | $127K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,684 | $122K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,015 | $120K |
| OP710 | <1% | 4,050 | $116K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,319 | $115K |
| OP251 | <1% | 8,755 | $109K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 1,227 | $103K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 986 | $101K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,162 | $100K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,021 | $99K |
| OP370 | <1% | 4,045 | $98K | |
| 73630 | <1% | 2,139 | $90K | |
| 90670 | <1% | 410 | $86K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,772 | $86K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,879 | $82K |
| 93971 | <1% | 320 | $78K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,146 | $77K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,029 | $74K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 419 | $64K |
| 73610 | <1% | 1,867 | $64K | |
| 80320 | <1% | 3,951 | $63K | |
| 73562 | <1% | 1,874 | $57K | |
| 93970 | <1% | 288 | $56K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,038 | $54K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 634 | $52K |
| 81003 | <1% | 22,241 | $51K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 632 | $51K |
| OP270 | <1% | 7,211 | $49K | |
| 73130 | <1% | 1,034 | $48K | |
| 80324 | <1% | 3,662 | $47K | |
| 76818 | <1% | 329 | $46K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,227 | $45K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,157 | $44K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,014 | $43K |
| 73030 | <1% | 1,411 | $42K | |
| 86850 | <1% | 3,675 | $39K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,875 | $39K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,779 | $38K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,533 | $37K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,958 | $35K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,406 | $34K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,264 | $32K |
| 80361 | <1% | 3,651 | $32K | |
| 84484 | <1% | 11,550 | $31K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,439 | $31K |
| 80061 | Lipid panel | <1% | 4,835 | $30K |
| 80345 | <1% | 3,646 | $30K | |
| 80349 | <1% | 3,645 | $30K | |
| 80353 | <1% | 3,648 | $30K | |
| 80346 | <1% | 3,644 | $30K | |
| 83992 | <1% | 3,658 | $29K | |
| 70486 | <1% | 494 | $29K | |
| 80358 | <1% | 3,645 | $29K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,254 | $28K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 3,337 | $28K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,546 | $27K |
| OP258 | <1% | 5,427 | $27K | |
| 87430 | <1% | 6,974 | $27K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 375 | $27K |
| 87070 | <1% | 7,585 | $24K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 507 | $22K |
| 87040 | <1% | 6,570 | $22K | |
| 85610 | <1% | 9,457 | $21K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,091 | $21K |
| 85027 | <1% | 4,803 | $21K | |
| 83880 | <1% | 3,022 | $20K | |
| 85730 | <1% | 8,847 | $19K | |
| 96376 | <1% | 3,814 | $19K | |
| 73110 | <1% | 602 | $17K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 939 | $17K |
| 97161 | <1% | 475 | $16K | |
| 90715 | <1% | 1,515 | $16K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,647 | $15K |
| 82803 | <1% | 2,883 | $15K | |
| 83735 | <1% | 8,835 | $15K | |
| 90837 | Psychotherapy session, about an hour | <1% | 700 | $15K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,355 | $15K |
| 84702 | <1% | 2,622 | $14K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 706 | $12K |
| 86900 | <1% | 3,779 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,603 | $12K |
| 83690 | <1% | 7,900 | $11K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,771 | $11K |
| 73080 | <1% | 230 | $11K | |
| 90674 | <1% | 759 | $10K | |
| 87807 | <1% | 2,402 | $10K | |
| 84100 | <1% | 6,376 | $10K | |
| 86481 | <1% | 272 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,104 | $9K |
| 96367 | <1% | 157 | $9K | |
| 72114 | <1% | 337 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,941 | $8K |
| 29580 | <1% | 246 | $8K | |
| 76770 | <1% | 114 | $8K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 211 | $8K |
| 83605 | <1% | 3,050 | $8K | |
| 0012A | <1% | 356 | $8K | |
| 88342 | <1% | 351 | $7K | |
| 87536 | <1% | 863 | $7K | |
| 82607 | <1% | 1,641 | $7K | |
| 90686 | <1% | 872 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 189 | $6K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,362 | $6K |
| 0011A | <1% | 370 | $6K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 25 | $6K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 360 | $6K |
| 90698 | <1% | 92 | $6K | |
| 97162 | <1% | 372 | $6K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 390 | $5K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 159 | $5K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 27 | $5K |
| 90677 | <1% | 52 | $5K | |
| 29581 | <1% | 119 | $5K | |
| 86360 | <1% | 834 | $5K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 794 | $4K |
| 87181 | <1% | 1,783 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,753 | $4K |
| 74022 | <1% | 121 | $4K | |
| 93225 | <1% | 16 | $3K | |
| 93226 | <1% | 16 | $3K | |
| 86592 | <1% | 1,134 | $3K | |
| 59425 | <1% | 567 | $3K | |
| 82728 | <1% | 541 | $3K | |
| 80329 | <1% | 126 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,843 | $3K |
| 72131 | <1% | 77 | $3K | |
| 77080 | <1% | 59 | $2K | |
| 86803 | <1% | 499 | $2K | |
| 94150 | <1% | 198 | $2K | |
| 85378 | <1% | 1,827 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 172 | $2K |
| 72100 | <1% | 57 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 15 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,182 | $2K |
| 82746 | <1% | 433 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 139 | $2K |
| 84439 | <1% | 606 | $2K | |
| 12001 | <1% | 25 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,362 | $2K |
| 29125 | <1% | 139 | $2K | |
| 74018 | <1% | 40 | $2K | |
| 90656 | <1% | 143 | $2K | |
| 86703 | <1% | 202 | $2K | |
| 72082 | <1% | 12 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 97 | $1K |
| 84436 | <1% | 523 | $1K | |
| 73140 | <1% | 107 | $1K | |
| 73590 | <1% | 79 | $1K | |
| 97116 | <1% | 81 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,322 | $1K |
| 86580 | <1% | 234 | $1K | |
| 59426 | <1% | 366 | $1K | |
| OP271 | <1% | 254 | $1K | |
| 0001A | <1% | 41 | $1K | |
| 90671 | <1% | 12 | $1K | |
| 82570 | <1% | 856 | $1K | |
| 73090 | <1% | 29 | $839.57 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 406 | $831.37 |
| 82043 | <1% | 584 | $824.53 | |
| 85651 | <1% | 1,021 | $819.04 | |
| 83550 | <1% | 352 | $787.03 | |
| 86140 | <1% | 690 | $766.69 | |
| 90680 | <1% | 14 | $717.73 | |
| 83540 | <1% | 394 | $709.80 | |
| 90685 | <1% | 52 | $663.91 | |
| 82550 | <1% | 620 | $640.04 | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 31 | $622.32 |
| G0008 | Administration of influenza virus vaccine | <1% | 637 | $607.41 |
| 84550 | <1% | 304 | $571.16 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 603 | $552.07 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 593 | $552.07 |
| 82248 | <1% | 170 | $545.90 | |
| 73502 | <1% | 76 | $534.56 | |
| 71250 | <1% | 21 | $462.02 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 279 | $458.99 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,701 | $449.52 |
| 99406 | <1% | 14 | $414.45 | |
| 83090 | <1% | 51 | $378.09 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 49 | $357.64 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,840 | $310.20 |
| 84145 | <1% | 131 | $307.06 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,728 | $302.06 |
| 99381 | <1% | 38 | $292.77 | |
| 90732 | <1% | 25 | $275.87 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 786 | $226.71 |
| 81002 | <1% | 99 | $218.65 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 56 | $217.84 |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 91 | $207.29 |
| 87340 | <1% | 48 | $186.44 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,820 | $185.42 |
| 84480 | <1% | 72 | $175.32 | |
| 83615 | <1% | 274 | $170.49 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 486 | $154.89 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 329 | $146.91 |
| 84703 | <1% | 40 | $123.45 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,472 | $118.06 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 585 | $112.20 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,003 | $106.08 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,616 | $96.06 |
| 82150 | <1% | 95 | $86.24 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 32 | $75.50 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 422 | $68.31 |
| 90694 | <1% | 16 | $53.21 | |
| 85044 | <1% | 14 | $42.20 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 21 | $34.98 |
| 87390 | <1% | 13 | $30.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 190 | $29.03 |
| 96127 | <1% | 24 | $28.48 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 318 | $26.54 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 202 | $25.10 |
| 81001 | <1% | 111 | $19.61 | |
| 86308 | <1% | 41 | $19.50 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 898 | $18.99 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 304 | $9.30 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 39 | $7.40 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 319 | $5.53 |
| 90461 | <1% | 12 | $3.54 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 161 | $2.18 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 26 | $2.18 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 36 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 56 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 48 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRODRIGUEZ, FRANK (MNGR. MANAGED CARE CONTRACTING/CRED)
| Provider | Location | Paid |
|---|---|---|
| Hudson Hospital Opco LLC | Jersey City, NJ | $52.54M |
| Ijkg Opco LLC | Bayonne, NJ | $17.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.